

Study of BHV-1300 in Graves' Disease

NCT06980649

| | |
|------------|----------------------------|
| Status | RECRUITING |
| Phase | Phase 1 |
| Sponsor | Biohaven Therapeutics Ltd. |
| Enrollment | 15 participants |

Key Eligibility Criteria

Inclusion (1)

- \. Participants must have serologically confirmed Graves' Disease.

Exclusion (2)

- History of hyperthyroidism not caused by Graves' Disease (e.g., toxic adenoma or toxic multinodular goiter) and/or history of thyroid storm within six weeks of the Baseline visit.
- History of treatment with radioactive iodine or thyroid surgery.

Locations (13 total)

Site-103, South Gate, California, United States
Site-100, Miami, Florida, United States
Site-104, Columbus, Georgia, United States
... and 10 more locations